Formulation of New Management Policy “Forging the future”
December 1, 2021
Updated on Feb. 24, 2023
Japanese ⇔ English
【further information】Notice regarding Specific Action Plan and Update of Performance Targets related to Management Policy "Forging the future"
Feb. 24, 2023「Mitsubishi Chemical Group Investor Day 2023」
>Briefing materials
Japanese ⇔ English
【further information】Notice regarding Specific Action Plan and Update of Performance Targets related to Management Policy "Forging the future"
Feb. 24, 2023「Mitsubishi Chemical Group Investor Day 2023」
>Briefing materials
Company name: Mitsubishi Chemical Holdings Corporation
Representative: Jean-Marc Gilson
Representative Corporate Executive Officer,
President & Chief Executive Officer
Listed on the 1st section of the TSE (stock code: 4188)
Contact: Osamu Shimizu
General Manager,
Corporate Communications Office
Tel: [+81] (0)3-6748-7120
Formulation of New Management Policy “Forging the future”
Mitsubishi Chemical Holdings Corporation (MCHC) has formulated a new management policy “Forging the future”, covering the period up to the end of FY 2025.
In February 2021, MCHC announced its medium-term management plan, “APTSIS 25 Step 1”, which covers the two years from FY 2021. “Forging the future" is a new management policy based on the assumptions made at the time the plan was formulated and on a review of the measures needed to maximize corporate value.
We aim to sustainably increase value for our stakeholders with a clearer strategy to drive operational excellence and unlock the growth potential of our businesses.
1.Growth, Performance, and Sustainability
2.Business to Exit
3.Strategic Cost Transformation
4.Leaner Structure to Execute Strategy
5.Strategic Capital Allocation
(1) Our Portfolio Assessment Criteria
We will focus on businesses in attractive markets where MCHC is positioned to win.
i. Market Attractiveness
・Market growth
・Potential Risk Factors
・ROS / ROIC / EBITDA Margin
ii. Strength
・No.1 / 2 Market Position Potential
・Technological Innovation
・Competitive Advantage
iii. Carbon Neutrality
・CO2 Emissions Level
・CO2 Reduction Potential
・Values to Customers / Society
(2) Our Strategic Focus
Based on the above evaluation criteria, Electronics and Health Care & Life Science will be positioned as our strategic focus.
[Our strategic focus]
[Electronics]
We will aim to achieve further growth in target domains by using MCHC’s key technologies.
[Health Care & Life Science]
We will lead innovation in targeted areas in the food sector, and in healthcare we will realize the value of late-stage development assets such as a potential coronavirus vaccine.
[Markets where we are strong: Solid performance materials businesses]
We will aim to further increase competitiveness in each of the domains including chemicals, polymers, films, and molding materials
[Markets where we are strong: Industrial gas]
We will take strategic initiatives to capture growth, reduce costs and improve profitability.
(3) Digitalization
By bolstering our digital strategy, we will enable customer experience and end-to-end business process transformations.
(4) Carbon Neutrality by 2050
We will take a practical path towards carbon neutrality by 2050 while achieving sustainable growth.
We will lead the consolidation of domestic basic chemical industries towards carbon neutrality by 2050 via restructuring, including through the carving out and future exit of our petrochemicals and coal chemicals.
We will reduce costs by more than 100 Billion yen per year by fiscal 2025 through the following measures for each item.
From April 1, 2022 onward, we will reform our organizational structure to create a flat organization with a "One Company, One Team" culture. In addition, we will shift from a legal entity-based to a business unit and corporate function-based operation to clarify where responsibility lies.
We will strategically reallocate available capital from operational efficiency and divestures.
Improved operational efficiency and financial strength create solid foundation for accelerated growth.
(1) Group target
(2) Targets by main segment
We will implement a firm strategy to increase shareholder value in accordance with the following road map.
Ⅰ.Strategic Priorities
1.Growth, Performance, and Sustainability
2.Business to Exit
3.Strategic Cost Transformation
4.Leaner Structure to Execute Strategy
5.Strategic Capital Allocation
1. Growth, Performance, and Sustainability
(1) Our Portfolio Assessment Criteria
We will focus on businesses in attractive markets where MCHC is positioned to win.
i. Market Attractiveness
・Market growth
・Potential Risk Factors
・ROS / ROIC / EBITDA Margin
ii. Strength
・No.1 / 2 Market Position Potential
・Technological Innovation
・Competitive Advantage
iii. Carbon Neutrality
・CO2 Emissions Level
・CO2 Reduction Potential
・Values to Customers / Society
(2) Our Strategic Focus
Based on the above evaluation criteria, Electronics and Health Care & Life Science will be positioned as our strategic focus.
[Our strategic focus]
We will aim to achieve further growth in target domains by using MCHC’s key technologies.
[Health Care & Life Science]
We will lead innovation in targeted areas in the food sector, and in healthcare we will realize the value of late-stage development assets such as a potential coronavirus vaccine.
[Markets where we are strong: Solid performance materials businesses]
We will aim to further increase competitiveness in each of the domains including chemicals, polymers, films, and molding materials
[Markets where we are strong: Industrial gas]
We will take strategic initiatives to capture growth, reduce costs and improve profitability.
(3) Digitalization
By bolstering our digital strategy, we will enable customer experience and end-to-end business process transformations.
(4) Carbon Neutrality by 2050
We will take a practical path towards carbon neutrality by 2050 while achieving sustainable growth.
2.Business to Exit
We will lead the consolidation of domestic basic chemical industries towards carbon neutrality by 2050 via restructuring, including through the carving out and future exit of our petrochemicals and coal chemicals.
3.Strategic Cost Transformation
We will reduce costs by more than 100 Billion yen per year by fiscal 2025 through the following measures for each item.
Major Item | Margin Impact | Value Levers |
Logistics / Supply Chain Management | ++ | ・Pursue efficiency through digitalization across entire process from manufacturing to sales |
Engineering repair and procurement | ++ |
・Optimization of investment through digital preventative maintenance ・Procurement process reformation and digitalization |
General and Administrative | + |
・Business reorganization - Integrate subsidiaries and offices - Introduction of new personnel system ・Process excellence and digitalization |
R&D | ++ |
・Clear prioritization ・Value impact - More selective R&D at Mitsubishi Tanabe Pharma ・Open innovation and Materials Informatics |
Price structure improvement | ++ | ・Price structure improvement of low-profit businesses |
4.Leaner Structure to Execute Strategy
From April 1, 2022 onward, we will reform our organizational structure to create a flat organization with a "One Company, One Team" culture. In addition, we will shift from a legal entity-based to a business unit and corporate function-based operation to clarify where responsibility lies.
5.Strategic capital allocation
We will strategically reallocate available capital from operational efficiency and divestures.
Ⅱ.Performance Targets for 2025
Improved operational efficiency and financial strength create solid foundation for accelerated growth.
(1) Group target
FY2020 Actual |
FY2021 Forecast |
FY2025 Base Target |
||
Group Revenues | JPY 3,258 Bil | JPY 3,886 Bil |
|
JPY 3,000 Bil |
Core Operating Income | JPY 175 Bil | JPY 300 Bil | JPY 350~370 Bil | |
EBITDA | JPY 406 Bil | JPY 530 Bil | JPY 540~560 Bil | |
EBITDA margin | 12.5% | 13.6% | 18~20% | |
EPS | JPY (-5.3) | JPY 108.6 | JPY 125-145 | |
Financial Leverage (Net Debt / EBITDA) |
5.3x | 3.8x | 2.0-3.0x | |
ROE | -0.6% | 11.0% | ≧10% | |
ROIC | 3.3% | 5.4% | > 7% |
(2) Targets by main segment
Performance Products | MMA | Healthcare |
Industrial Gas (Request-based) |
|
EBITDA | ≈ JPY 180 Bil | ≈ JPY 70 Bil | ≈ JPY 70 Bil | ≈ JPY 220 Bil |
EBITDA margin | ≈ 15% | ≈ 26% | ≈ 15% | ≈ 25% |
Ⅲ.Road Map
We will implement a firm strategy to increase shareholder value in accordance with the following road map.
Forward-Looking Statements
Forward-looking statements are based largely on the Company’s expectations and information available as of the date hereof, and are subject to risks and uncertainties which may be beyond the Company’s control. Actual results could differ materially due to numerous factors, including but not limited to market conditions and the impact of competition within the industry.